MAP2K1 and central nervous system cancer: The MEK1/2 inhibitor trametinib is approved for adult BRAF V600E mutant cancers (ie. NCT01682083) and is also currently undergoing testing in both refractory low-grade gliomas and plexiform neurofibromas (NCT03363217, NCT02124772)51,52.